Stevanato group reports record revenue of €1,104 million for fiscal year 2024

Piombino dese, italy--(business wire)--stevanato group s.p.a. (nyse: stvn), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and fiscal year 2024. fourth quarter and full-year 2024 highlights (comparisons to prior-year period) revenue for the fourth quarter of 2024 increased 3% to €330.6 million, and high-value solutions represent.
STVN Ratings Summary
STVN Quant Ranking